Compare Roundhill Magnificent Seven ETF (MAGS) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Magnificent Seven ETF vs ResMed Inc. — how do they compare? Roundhill Magnificent Seven ETF trades at $73.73 (market cap $5.78B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 5.5× Roundhill Magnificent Seven ETF's market cap, and ResMed Inc. pays a 1.16% dividend while Roundhill Magnificent Seven ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill Magnificent Seven ETF for 36 Days and ResMed Inc. for 51 Days on average.
| MAGS | RMD | |
|---|---|---|
Market Cap | $5.78B | $31.89B |
Volume | 4,410,665 | 618,314 |
Sector | Sector/Thematic | Health |
52-Week High | $73.90 | $275.96 |
52-Week Low | $55.39 | $182.82 |
Typical Hold Time | 36 Days | 51 Days |
Enterprise Value | — | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAGS trades at $73.03, down 0.9% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF provides equal-weighted exposure to the Magnificent Seven tech stocks, though 2026 performance has been muted with a 2% year-to-date gain as the group faces increased competition and AI spending pressures. Recent news highlights both the long-term AI growth theme and near-term underperformance versus the broader market.
The outlook hinges on AI-driven earnings growth from its mega-cap holdings, but concentration risk and shifting investor sentiment pose challenges. Upside potential exists if the Magnificent Seven reassert leadership, while downside risks include prolonged sector rotation and margin compression from heavy capital expenditure.
ResMed (RMD) trades at $226.73, up 0.33% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming Q1 2027 earnings report and management's focus on 12%-14% EPS growth driven by demand in sleep therapy.
The outlook for RMD is positive, supported by robust fundamentals and analyst consensus, though risks include competitive pressures and ongoing legal investigations. Upside potential exists with a consensus price target of $242.70, representing a 7% increase from current levels, but investors should monitor execution against growth targets and market share dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
